Secukinumab Improves Symptoms in TNF Inhibitor-Refractory Rheumatoid Arthritis
A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active rheumatoid arthritis who received secukinumab, abatacept, or placebo.